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Nuclear hormone receptors are tran-
scription factors that regulate the 
expression of target genes by binding to 
regulatory DNA sequences and interact-
ing with co-regulatory protein complex-
es. A large molecular family of these 
receptors has been identified by homo-
logy searches. Soon after the sequences 
became available, individual receptors 
were characterized for their tissue distri-
bution, ligand identity, patterns of target 
gene activation, and interaction with 
co-regulatory proteins. To better under-
stand their physiological roles, individ-
ual receptors were tested in genetic ani-
mal models of loss and gain of function.
In this fashion, peroxisome proli-
ferator-activated receptor-α (PPARα) was 
found to be a nuclear hormone recep-
tor that is activated by fatty acid-derived 
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Overexpression of PPAR-α, a developmental transcription factor important in 
epidermal embryogenesis, in basal keratinocytes causes epidermal thinning 
when activated constitutively during development, but not if activated in adults; 
and lack of PPAR-α transiently delays stratum corneum formation within a win-
dow late in epidermal development (day 18.5 to birth). In contrast, pharmaco-
logic activation of PPAR-α inhibits proliferation and induces differentiation in 
mouse epidermis regardless of developmental stage. Thus, PPAR-α is an impor-
tant regulator of epidermal homeostasis.
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ligands. Since Issemann and Green 
cloned mouse PPARα in 1990 and Sher 
et al. cloned its human homologue in 
1993 (Issemann and Green, 1990; Sher 
et al., 1993), several groups have gener-
ated mouse models of PPARα deficiency. 
Such animals displayed abnormal lipid 
and xenobiotic metabolism in the liver, 
heart, muscle, and kidney, indicating 
a role of PPARα in fatty acid oxidation 
and detoxification of xenobiotic com-
pounds. Although PPARα was originally 
evaluated for its systemic activities, its 
expression was soon also noted in skin.
PPARα is present in both epidermis 
and dermis beginning at day 13.5 of 
development. Yet shortly after birth it 
becomes undetectable in the interfol-
licular epidermis, although expression 
persists in the hair follicles (Michalik 
et al., 2001). Injury to adult murine 
skin, such as hair plucking, induces 
re-expression of PPARα in the adult 
interfollicular epidermis, and re-expres-
sion can also be observed in the edges 
of full-thickness wounds. Conversely, 
in PPARα-deficient mice, the early 
phase of wound healing is delayed, 
and this delay is retained when the 
deficiency is targeted to the epidermis 
only and not to the dermis (Michalik 
et al., 2005). In pups lacking PPARα, a 
delay in stratum corneum formation is 
observed between day 18.5 of epider-
mal development and birth (Schmuth et 
al., 2002), whereas in PPARα-deficient 
adults, only a modest decrease in the 
expression of involucrin, loricrin, and 
filaggrin persists. This indicates that 
other mediators can compensate for 
the absence of PPARα; that is, there is 
redundancy (Komuves et al., 2000).
In this issue, Gonzalez et al. (2006) 
report on the skin phenotype of trans-
genic mice constitutively overexpress-
ing PPARα in the epidermis. These mice 
die within 2 days after birth, presum-
ably because of abnormal development 
of the tongue and mammary gland epi-
thelia; overexpression of PPARα also 
results in epidermal thinning and sparse 
fur in these animals, which could con-
tribute to the lethality. Importantly, cor-
responding to the transient effects of 
PPARα deficiency on developing epi-
dermis, PPARα overexpression exerts 
its effects only during a developmental 
window; that is, after birth it does not 
cause the abnormalities.
Consequences of a gain of PPARα 
function have previously been stud-
ied using pharmacologic activators. In 
explants of developing rat epidermis, the 
expression of proteins required for epi-
dermal differentiation (filaggrin, loricrin, 
involucrin) was stimulated by the PPARα 
agonist farnesol (Hanley et al., 1997). In 
contrast to the VP16PPAR-α bitransgen-
ic mice reported here (Gonzales et al., 
2006), there was a concomitant induc-
tion of the granular layer. These differ-
ences could be explained by differences 
between in vitro and in vivo experimen-
tal systems and by differences in the tim-
ing of the PPARα signal. Nevertheless, 
in adult mice, pharmacologic activation 
of PPARα induces epidermal differentia-
tion, inhibits proliferation, and increases 
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keratinocyte death. These effects are 
absent in PPARα knockout mice, which 
indicates that they are specifically medi-
ated via PPARα (Komuves et al., 2000). 
Consistent with these findings, Gonzales 
et al. (2006) report here an increase in 
p21 (Waf1/Cip1) in cultured keratino-
cytes from 1-day-old neonate mice over-
expressing PPARα, which, by causing an 
arrest in the G1 phase of the cell cycle, 
may account for the coordinate regula-
tion of proliferation, differentiation, and 
cell death.
How do these results complement 
our current knowledge on the transcrip-
tional regulation of epidermal develop-
ment? Aside from p21, which has been 
shown to act as a negative regulator of 
transcription, linking the Notch and 
Wnt signaling pathways in the control 
of keratinocyte growth (Devgan et al., 
2005), additional transcription factors 
have been implicated in skin morpho-
genesis. Whereas LEF-1 and TCF-3 have 
primarily been investigated for their role 
in the epidermal stem cell niche (Merrill 
et al., 2001), the work of Gonzales et al. 
(2006) implies that PPARα is involved in 
controlling the switch from proliferating 
basal to differentiating suprabasal kera-
tinocytes. The precise compartmental 
roles of PPARα remain to be determined, 
and it is certainly only one of multiple 
transcription factors involved in control-
ling epidermal transcription and is likely 
to interact with additional factors — p63, 
SP-1, the activator protein-1 transcrip-
tion factor gene family, c-Myc, RelA, 
pRb, Klf4, and others (Dai and Segre, 
2004). The challenge of future investiga-
tions in this field will be to delineate a 
more complete and possibly quantitative 
map of interactions among these factors 
to obtain a better understanding of how 
epidermal development is orchestrated.
Although it is clear that ligand binding 
controls the biological activity of PPARα, 
the specific lipid ligands that PPARα 
senses physiologically in keratinocytes 
remain unknown. There is a large num-
ber of potential long-chain unsaturated 
fatty acid ligands, including eicosanoids 
and leukotrienes, and it is likely that, 
physiologically, more than one lipid 
compound is involved. The levels of a 
variety of ligands, rather than the level of 
one specific lipid, may be important in 
determining the activity of the receptor 
during epidermal development. Because 
PPARα regulates genes of lipid metabo-
lism, a feedback loop is likely to exist. 
Additionally, some lipids may be potent 
activators whereas other lipids may actu-
ally behave as antagonists. The pheno-
type of the PPARα-overexpressing mice 
generated by the Gonzalez group sup-
ports the notion of cross-talk between 
epidermal lipids and the proteins 
involved in epidermal development.
Because PPARα can be activated 
by ligands, the results from the cur-
rent report provide the rationale for 
the development of tailored drugs 
targeting this receptor. In addition to 
a role in epidermal proliferation and 
differentiation, PPARα activation has 
also been shown to be anti-inflam-
matory, and the delay in wound heal-
ing in PPARα-deficient mice has been 
ascribed to impaired neutrophil and 
monocyte recruitment during the initial 
inflammatory phase of wound healing 
(Michalik et al., 2001). The combina-
tion of these effects could be benefi-
cial in the treatment of inflammatory 
skin disease associated with disturbed 
epidermal homeostasis. Even though 
extrapolation from mouse to human is 
perilous, this research should stimulate 
translational studies in humans that 
may lead to new avenues of therapeu-
tic intervention for common dermato-
logic skin disease.
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